Insilico Medicine has recently announced the breakthrough study achieved in collaboration with a well-known university in Hong Kong. (IMAGE)

InSilico Medicine

Insilico Medicine has recently announced the breakthrough study achieved in collaboration with a well-known university in Hong Kong.

Caption

Targeting endometriosis, a condition that affects more than 190 million women worldwide, the researchers used Insilico’s PandaOmics, the artificial intelligence-driven platform, to identify two novel therapeutic targets and a FDA approved drug as a potential repurposed treatment option. The findings were published in December 2024 in Advanced Science（IF=15.1）.

Credit

Advanced Science

Usage Restrictions

No restrictions.

License

Public Domain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.